The role of the CD95, CD38 and TGFbeta1 during active human cytomegalovirus infection in liver transplantation.
OBJECTIVE
Human cytomegalovirus (HCMV) has highly evolved mechanisms for avoiding detection by the host immune system. The aim of this study was to analyze the expression levels of TGFbeta1, soluble form of CD95, CD95 ligand (sCD95 and sCD95L, respectively) in plasma and CD95 expression on CD3(+) cells, CD38 expression on CD8(+) cells in liver transplanted recipients with active HCMV infection.


METHODS
Blood samples were collected from 15 liver transplanted recipients with active HCMV infection and 15 recipients without HCMV infection. CD95 expression on CD3(+) cells and CD38 expression on CD8(+) cells were quantitatively detected with two-color fluorescence activated cell sorter (FACS) analysis. Lymphocyte surface phenotypes of CD4 and CD8 were detected with FACS analysis. Plasma sCD95, sCD95L and TGFbeta1 levels were determined with enzyme linked-immuno-sorbent assay (ELISA). The results were compared with that from 15 healthy individuals.


RESULTS
CD95 expression on CD3(+) T-cells and CD38 expression on CD8(+) cells were significantly increased in active HCMV infection group compared with that in stable group or healthy group (P<0.01). No significant difference was seen between stable group and healthy group (P>0.05). The percentages of CD4(+) T-cell and CD4/CD8 ratio in active HCMV infection group were significantly lower than the values in stable group and healthy group (P<0.05). Plasma levels of TGFbeta1 and sCD95 were significantly increased in active HCMV infection group compared to stable group and healthy group (P<0.05). In contrast, plasma levels of sCD95L in healthy group were not significantly different from that expressed in active HCMV infection group and stable group (P>0.05).


CONCLUSIONS
HCMV suppress proliferation of activated T cells by apoptosis and by releasing immunosuppressive cytokine TGFbeta1. This may provide an important clue to a better understanding of the pathogenesis in liver transplanted recipients with active HCMV infection.
Wang
Yuliang
Y
Department of Immunology, Tianjin Medical University, Heping District, Qi xiangtai road, No.22, 300070 Tianjin, PR China.
Liu
Yawu
Y
Zhang
Yanyan
Y
Peng
Lin
L
Ma
Jun
J
Tang
Zhiqin
Z
Gao
Wei
W
Zhu
Zhijun
Z
Yao
Zhi
Z
D051997:ADP-ribosyl Cyclase 1 / Q000097:blood*; D000328:Adult; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D016022:Case-Control Studies; D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000276:immunology*; D005260:Female; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000276:immunology; D053773:Transforming Growth Factor beta1 / Q000097:blood*; D019014:fas Receptor / Q000097:blood*
D008562:Membrane Glycoproteins; D053773:Transforming Growth Factor beta1; D019014:fas Receptor; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1